Danazol low-dose - Ampio Pharmaceuticals

Drug Profile

Danazol low-dose - Ampio Pharmaceuticals

Alternative Names: Optina; Vasaloc

Latest Information Update: 06 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ampio Pharmaceuticals
  • Class Oxazoles; Small molecules
  • Mechanism of Action Actin modulators; Capillary permeability modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Diabetic macular oedema

Highest Development Phases

  • Phase III Diabetic macular oedema
  • No development reported Allergic rhinitis; Diabetic nephropathies; Diabetic retinopathy; Wet age-related macular degeneration

Most Recent Events

  • 31 Dec 2016 Ampio Pharmaceuticals has patent protection for donazol low-dose for the treatment of Macular oedema or Diabetic nephropathy in USA, Australia, Europe, Hong Kong, Japan, Mexico, New Zealand, South Africa, Singapore and Canada
  • 31 Dec 2016 Ampio Pharmaceuticals has patents pending for danazol low-dose in USA, Australia, Brazil, China, Canada, Eurasia, Europe, Indonesia, Israel, Japan, Korea, Mexico, Malaysia, Philippines, Singapore and Hong Kong
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Diabetic-nephropathies in Canada (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top